<DOC>
	<DOCNO>NCT02452606</DOCNO>
	<brief_summary>The purpose study investigate genetic variant clock narcolepsy gene determine therapeutic effect Stalevo® quality sleep patient Parkinson 's Disease .</brief_summary>
	<brief_title>Clock Narcolepsy Genetic Variants Effects Stalevo® ( Levodopa/Carbidopa/Entacapone ) Sleep Disorders Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Sleep Wake Disorders</mesh_term>
	<mesh_term>Parasomnias</mesh_term>
	<mesh_term>Narcolepsy</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Entacapone</mesh_term>
	<criteria>1 . Patients diagnose PD accordance UK Parkinson 's Disease Society Brain Bank Clinical Diagnostic Criteria ( Hughes AJ , et al . 1992 ) . 2 . Patients PD wear phenomenon . 3 . Patients PD Hoehn Yahr stage 14 . 4 . Patients PD sleep problem ( PDSS score ≤120 Epworth Sleepiness Scale ( ESS ) score ≥ 8 ) . 5 . Patients PD show Montreal Cognitive Assessment ( MoCA ) score ≥15 . 6 . Patients PD major depression ( Geriatric depression scale , GDS ≤ 24 ) 1 . Secondary parkinsonism 2 . Parkinsonplus syndrome ( multiple system atrophy , progressive supranuclear palsy , corticobasal degeneration . 3 . Patients PD history severe side effect Stalevo® .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Stalevo</keyword>
	<keyword>sleep disturbance</keyword>
	<keyword>central circadian clock</keyword>
	<keyword>narcolepsy</keyword>
</DOC>